Reports on Gene Therapy Findings from Tongji University Provide New Insights (Deficiency of Transcription Factor Sp1 Contributes To Hypertrophic Cardiomyopathy).
In: Gene Therapy Weekly, 2024-03-08, S. 689-689
serialPeriodical
Zugriff:
A recent study conducted at Tongji University in Shanghai, China, has shed light on the pathogenesis of hypertrophic cardiomyopathy (HCM), the most prevalent monogenic heart disorder. The researchers focused on the role of the transcription factor SP1 in the growth of cardiomyocytes and cardiac hypertrophy associated with HCM. Through experiments on mice and human induced pluripotent stem cell-derived cardiomyocytes, they found that SP1 deficiency contributes to the development of HCM. Furthermore, they discovered that SP1 overexpression has therapeutic effects on HCM, suggesting it could be a potential intervention target for the disease. This research was supported by the National Natural Science Foundation of China. [Extracted from the article]
Copyright of Gene Therapy Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Reports on Gene Therapy Findings from Tongji University Provide New Insights (Deficiency of Transcription Factor Sp1 Contributes To Hypertrophic Cardiomyopathy).
|
---|---|
Zeitschrift: | Gene Therapy Weekly, 2024-03-08, S. 689-689 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1078-2842 (print) |
Sonstiges: |
|